Monti S, Delvino P, Riboli M, et al. - By analyzing available evidence from relevant randomized controlled studies and observational studies, researchers sought to determine if trimethoprim/sulfametoxazole (TMP/SMX) has any role in decreasing the relapse rate in patients suffering from granulomatosis with polyangiitis (GPA) as well as the risk of infections in patients suffering from anti-neutrophil cytoplasm antibody-associated vasculitis. Of 2,907 records, eight studies were eligible. Findings revealed there was no link of TMP/SMX with a decreased relapse risk in patients with GPA. A likely benefit of TMP/SMX in decreasing infectious complications was suggested.